Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880536
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880549
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
- Conditions
- InfluenzaSARS-CoV-2
- Interventions
- Biological: mRNA-1083 Composition 1 Dose A Lot ABiological: mRNA-1083 Composition 1 Dose A Lot BBiological: mRNA-1083 Composition 1 Dose BBiological: mRNA-1083 Composition 1 Dose CBiological: mRNA-1083 Composition 2 Dose ABiological: mRNA-1083 Composition 2 Dose BBiological: mRNA-1083 Composition 3 Dose ABiological: mRNA-1083 Composition 3 Dose BBiological: Investigational Influenza VaccineBiological: Investigational COVID-19 Vaccine Lot ABiological: Investigational COVID-19 Vaccine Lot B
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT06864143
- Locations
- 🇺🇸
Headlands Research Scottsdale, Scottsdale, Arizona, United States
🇺🇸Artemis Research (Headlands), San Diego, California, United States
🇺🇸Clinical Research Atlanta (Headlands), Stockbridge, Georgia, United States
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT06735248
- Locations
- 🇺🇸
ANESC Research, El Paso, Texas, United States
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
- Conditions
- COVID-19Influenza
- Interventions
- Biological: Licensed Influenza VaccineOther: Placebo
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 2457
- Registration Number
- NCT06694389
- Locations
- 🇯🇵
Public Health Association.Inc., Nagoya-shi, Aichi, Japan
🇯🇵Daido Clinic, Nagoya-shi, Aichi, Japan
🇯🇵Tenjin Sogo Clinic, Fukuoka-shi, Fukuoka, Japan
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06655870
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06634797
- Locations
- 🇺🇸
Velocity Clinical Research, Phoenix, Phoenix, Arizona, United States
🇺🇸Velocity Clinical Research, Huntington Park, Huntington Park, California, United States
🇺🇸Velocity Clinical Research, San Diego, La Mesa, California, United States
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
- Conditions
- Seasonal Influenza
- Interventions
- Biological: Fluarix®Biological: Influsplit® TetraBiological: Fluarix TetraBiological: Alpharix® Tetra
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 56000
- Registration Number
- NCT06602024
- Locations
- 🇺🇸
Pinnacle Research Group, Llc, Anniston, Alabama, United States
🇺🇸North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸Flourish Research, Covina, California, United States
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
- Conditions
- Acute GastroenteritisNorovirus Acute Gastroenteritis
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 27776
- Registration Number
- NCT06592794
- Locations
- 🇺🇸
Accel Research Sites - Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Daphne, Alabama, United States
A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273 Variant-containing Formulation
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06585241
- Locations
- 🇺🇸
CenExel iResearch, LLC, Decatur, Georgia, United States